Quick Answer
Semnur Pharmaceuticals, Inc. reported Cash and Equivalents of $20.0 thousand for fiscal year 2025.
Semnur Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.0K | +66.7% |
| 2024 | $12.0K | -94.1% |
| 2023 | $204.5K | -75.1% |
| 2022 | $819.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $85.0K | — | +608.3% |
| December 31, 2024 | $12.0K | -94.1% | +1084.6% |
| March 31, 2024 | $1.0K | — | -99.5% |
| December 31, 2023 | $204.5K | — | — |
- Semnur Pharmaceuticals, Inc. showed an increase of +66.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, Semnur Pharmaceuticals, Inc.’s cash and equivalents has declined by 97.6% (from $819.7 thousand to $20.0 thousand).
- The most recent figure is from Semnur Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: